GSA Capital Partners LLP Buys Shares of 20,633 Pediatrix Medical Group, Inc. $MD

GSA Capital Partners LLP purchased a new position in Pediatrix Medical Group, Inc. (NYSE:MD) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 20,633 shares of the company’s stock, valued at approximately $523,000.

Other large investors also recently modified their holdings of the company. Global Retirement Partners LLC boosted its position in shares of Pediatrix Medical Group by 68,250.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock valued at $29,000 after acquiring an additional 1,365 shares during the period. Transamerica Financial Advisors LLC bought a new position in Pediatrix Medical Group during the fourth quarter worth $30,000. Eurizon Capital SGR S.p.A. bought a new position in Pediatrix Medical Group during the fourth quarter worth $33,000. TD Private Client Wealth LLC acquired a new position in Pediatrix Medical Group during the 4th quarter valued at $39,000. Finally, Los Angeles Capital Management LLC acquired a new position in Pediatrix Medical Group during the 4th quarter valued at $43,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Pediatrix Medical Group Stock Up 1.4%

Shares of MD opened at $26.59 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.45. The company has a 50-day moving average price of $25.77 and a two-hundred day moving average price of $22.97. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of 12.72 and a beta of 0.66. Pediatrix Medical Group, Inc. has a 12 month low of $15.69 and a 12 month high of $27.94.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The company had revenue of $487.78 million for the quarter, compared to analyst estimates of $478.49 million. During the same period in the prior year, the company posted $0.53 EPS. The company’s revenue was up 4.1% compared to the same quarter last year. Equities analysts predict that Pediatrix Medical Group, Inc. will post 2.17 EPS for the current fiscal year.

Key Stories Impacting Pediatrix Medical Group

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Zacks increased its FY2026 EPS estimate to $2.11 from $2.02 and lifted its Q2 2027 forecast to $0.53 from $0.50. The firm also raised its FY2027 estimate to $2.10 from $1.94 and its FY2028 estimate to $2.04 from $1.88.
• Positive Sentiment: Quarterly estimates were raised for Q1 2027 to $0.37 from $0.34, Q3 2027 to $0.57 from $0.50, Q4 2027 to $0.63 from $0.59, and Q2 2028 to $0.49 from $0.43. These revisions suggest analysts see improving earnings potential beyond the current year.
• Positive Sentiment: Zacks also characterized MD as a strong momentum stock, which may attract additional buying from investors using quantitative or style-based strategies. Here’s Why Pediatrix Medical Group Is a Strong Momentum Stock
• Neutral Sentiment: The current-year consensus EPS forecast remains $2.15, above Zacks’ revised $2.11 estimate for FY2026, indicating that the upgrades have not yet translated into a broader consensus increase.
• Negative Sentiment: Zacks lowered its Q1 2028 EPS forecast to $0.34 from $0.36, a relatively minor negative revision that partly offsets the broader pattern of upward estimate changes.

Analysts Set New Price Targets

Several analysts have issued reports on MD shares. Jefferies Financial Group lowered shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating and raised their price target for the stock from $27.00 to $28.00 in a research report on Wednesday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $25.00 price objective on shares of Pediatrix Medical Group in a research report on Wednesday, August 5th. Truist Financial increased their target price on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. Mizuho set a $24.00 target price on Pediatrix Medical Group in a research report on Friday, May 8th. Finally, UBS Group boosted their price target on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of “Hold” and a consensus price target of $25.00.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.